Bears Bet On Moderna, Enphase, SMCI, and More
When short-sellers (bears) bet heavily against companies on the S&P 500 (IVV), investors should not ignore them.Enphase (ENPH) had a 23.22% short interest at the end of July. The energy technology firm dropped after it warned of lower revenue in the third quarter. It expects the U.S. residential solar market revenue to fall by 20% in the year. ENPH stock peaked at $130.08. The share price closed below $35 last week.Moderna (MRNA), best known for its mRNA-based Covid vaccine during the pandemic, attracted an 18.29% short interest. In July, the firm posted a 39% Y/Y decline in net loss. Cost cuts helped cut expenses. The issue is the severe pressure from lower Covid vaccine sales. Moderna does not have an RSV vaccine or other products to offset its reliance on Covid vaccine sales.Super Micro Computer (SMCI) bears held a 17.5% short interest. They lowered their short position from 18.6% on June 30. SMCI stock performed well this year. More recently, however, SMCI stock formed a bearish “double top” at over $60.In the advertising space, Omnicom Group (OMC) had 16.5% short interest. Artificial Intelligence may easily create advertorial images and videos. This will cut into Omnicom’s business.Campbell’s (CPB) had 13.6% short interest. Food suppliers face lower sales as inflation cuts into consumer spending.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


